Supported by an educational grant from Otsuka America Pharmaceutical, Inc.
Clinicians who diagnose and treat autosomal-dominant polycystic kidney disease (ADPKD) are witnessing the dawn of a new era. For the first time, targeted therapies offer the promise of delaying progression in ADPKD—dramatically altering a therapeutic landscape that until recently was exclusively symptom-focused and offered some subgroups only modest delays in progression through rigorous blood-pressure lowering. The management of ADPKD has undergone a paradigm shift following the approval of tolvaptan in April 2018 as a novel therapy to slow progression of cyst development and renal insufficiency in selected patients. In this program, a panel of experts in the management of ADPKD—and 3 patients with ADPKD—share their insights on real-world ADPKD management, including diagnosis, risk assessment, strategies for initiation and monitoring of treatment, and collaboration with a multispecialty, interprofessional team to address the complexities of care, including comorbidities, pain management, and genetic counseling.
Nephrologists, pediatric nephrologists, internists, pediatricians, family physicians, pain specialists, urologists, cardiologists, and other members of the multidisciplinary care team who may see patients with ADPKD.
After completing the activity, the participant should be better able to:
Identify patients who are likely to benefit from treatment with tolvaptan or other emerging agents that have been demonstrated in clinical trials to delay progression of ADPKD
Monitor changes in renal function and total kidney volume (TKV) using appropriate laboratory and imaging modalities and validated risk-stratification and staging systems to assess disease progression and response to treatment
Initiate treatment with tolvaptan or other emerging therapies in accordance with approved indications and mandated monitoring strategies
Collaborate with a multispecialty, interprofessional team to address the complexities of care, including comorbidities, pain management, and genetics
Conflict Of Interest Disclosure Policies
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Ronald D. Perrone, MD Scientific Director Clinical and Translational Research Center Associate Chief, Division of Nephrology Professor Tufts University School of Medicine Tufts Medical Center Boston, MA
Dr. Perrone is a consultant for Otsuka America Pharmaceutical, Inc., Palladio Biosciences, Sanofi-Genzyme, and Vertex Pharmaceuticals. He is on the speakers’ bureau for Otsuka America Pharmaceutical, Inc., and receives research grant funds from Kadmon Corporation, Otsuka America Pharmaceutical, Inc., Reata Pharmaceuticals, Inc., Sanofi-Genzyme, and the US Department of Defense.
Simin O. Goral, MD Director, Polycystic Kidney Disease Clinic Transplant Nephrology Fellowship Director Professor of Medicine Hospital of the University of Pennsylvania Philadelphia, PA
Dr. Goral receives research grant funds from Astellas Pharma, AstraZeneca, Kadmon Corporation, and Otsuka America Pharmaceutical, Inc.
Osama W. Amro, MD, MS Swedish Medical Center National Kidney Foundation Advisory Board Seattle, WA
Dr. Amro is a consultant and on the speakers’ bureau for Otsuka America Pharmaceutical, Inc.
Pranav S. Garimella, MBBS, MPH, FASN Assistant Professor of Medicine (Nephrology) Division of Nephrology and Hypertension UC San Diego School of Medicine La Jolla, CA
Dr. Garimella receives research grant funds from Kadmon Corporation.
Paul P. Doghramji, MD, FAAFP (Moderator) Senior Family Physician Collegeville Family Practice Medical Director of Health Services Ursinus College Collegeville, PA
Dr. Doghramji has no relevant financial relationships to disclose.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
Physician Assistant Continuing Education The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credit for completing this activity.
Nurse Practitioner Continuing Education The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Otsuka America Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Learners will review the materials on accreditation information, target audience, learning objectives, and disclosure information; complete the pre-test; review the content; and complete the post-test (minimum score of 70% required; learners will only have 3 attempts to pass the post-test) and evaluation to successfully earn credit.